Ani Phar­ma picks up gener­ic play­er for a cool $210M, tur­bocharg­ing its man­u­fac­tur­ing and R&D wings

Con­tract man­u­fac­tur­ing work has grown at a rapid clip the past year giv­en de­mand caused in part by Covid-19. Big play­ers are dou­bling down on their pro­duc­tion foot­prints, and even small play­ers are tak­ing big swings to get in­to the game.

Min­neso­ta’s Ani Phar­ma­ceu­ti­cals will shell out $89.5 mil­lion in cash and $74 mil­lion in eq­ui­ty to ac­quire New Jer­sey gener­ics play­er Novi­tium Phar­ma, al­low­ing it rapid­ly scale its man­u­fac­tur­ing and R&D in­fra­struc­ture for gener­ics, the drug­mak­er said this week.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.